Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

(2010) E. Terpos et al.   ANNALS OF ONCOLOGY

Neutralisation of Dkk-1 protects from systemic bone loss during inflammation and reduces sclerostin expression

(2010) G. R. Heiland et al.   ANNALS OF THE RHEUMATIC DISEASES

A sclerostin-based theory for strain-induced bone formation

(2010) René F. M. van Oers et al.   Biomechanics and Modeling in Mechanobiology

Sclerostin: Current Knowledge and Future Perspectives

(2010) M. J. C. Moester et al.   CALCIFIED TISSUE INTERNATIONAL

Sclerostin and Dickkopf-1 in Renal Osteodystrophy

(2010) D. Cejka et al.   Clinical Journal of the American Society of Nephrology

Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones

(2010) Michael S Ominsky et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Increased Sclerostin Serum Levels Associated with Bone Formation and Resorption Markers in Patients with Immobilization-Induced Bone Loss

(2010) Agostino Gaudio et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures

(2010) P. D’Amelio et al.   OSTEOPOROSIS INTERNATIONAL

Pathogenesis and management of myeloma bone disease

(2009) Dimitrios Christoulas et al.   Expert Review of Hematology